Comparison · NCT04281472-d754b83d
Stage B: Efgartigimod PH20 SC vs Stage B: Placebo PH20 SC: Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stage B: Efgartigimod PH20 SC vs Stage B: Placebo PH20 SC: Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline. Trial comparisons, record NCT04281472-d754b83d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04281472-d754b83d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.45 | 0.361 | 0.543 | wilson | |
| Risk in group 2 | 0.364 | 0.28 | 0.457 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0868 | -0.0422 | 0.212 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 0.898 | 1.71 | log | |
| Odds ratio, group 1 over group 2 | 1.43 | 0.837 | 2.46 | log | |
| Number needed to treat, for one more participant with the outcome on Stage B: Efgartigimod PH20 SC than on Stage B: Placebo PH20 SC | 11.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stage B: Efgartigimod PH20 SC | Participants who completed stage A and received efgartigimod PH20 SC in stage B | 50 | 111 | OG000 |
| Group 2 | Stage B: Placebo PH20 SC | Participants who completed stage A and received placebo PH20 SC in stage B | 40 | 110 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline
- Description
- Time frame
- Up to 48 weeks during the randomized placebo-controlled stage B
- Population
- mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B.
Source ClinicalTrials.gov
Trial
- Title
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- NCT number
- NCT04281472
- Phases
- PHASE2
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- efgartigimod PH20 SC in stage B, placebo in stage B
- Lead sponsor
- argenx
- Results first posted
- 2024-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04281472?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04281472-d754b83d